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Introduction
Schizophrenia is a chronic and severe mental disorder 
characterized by abnormal social behavior and failure to 
understand reality [1]. Clinically, the disorder manifests with a 
large variety of symptoms that fall into three categories: positive, 
negative, and cognitive [2]. Schizophrenia affects about 1.1% of 
world wide population [3]. Although schizophrenia is not as 
common as other mental disorders such as anxiety disorder 
(18.1%) [4], depression (6.9%) [5], and bipolar disorder (2.6%) 
[6], the symptoms can be very disabling. Therefore, it is often 
associated with high levels of morbidity and mortality [7]. The 
average life expectancy of people with schizophrenia is ten to 
twenty-five years less than for the general population [8]. This 
is the result of increased physical health problems and a higher 
suicide rate (about 10%) [9,10]. 
Although scientists believe that a combination of genetics, 
environment, and altered brain chemistry and structure may 
 
play a role in the development of schizophrenia [11], the exact 
cause of this disorder is still unknown to the research community. 
Consequently, there is no cure for this disorder and treatments 
have been focusing on eliminating the symptoms of the disease. 
The primary treatment of schizophrenia is antipsychotic 
medications [12], often in combination with psychological and 
social supports. While the current FDA-approved antipsychotic 
drugs are able to reduce the positive symptoms of schizophrenia 
in about 7 to 14 days [13,14], they have limited efficacy with 
negative and/or cognitive symptoms [15,16]. 
Furthermore, antipsychotic medications can greatly lower 
the patients’ life quality by inducing a wide range of motor, 
metabolic, cardiovascular, and emotional side effects which 
also lead to treatment noncompliance [14,17]. Therefore, it is 
of great necessity to develop novel pharmaco therapies which 
have better efficacies for treating all three clinical schizophrenia 
symptoms and possess a low profile for side effects.
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Abstract
Functionally selective ligands (also known as biased ligands) of dopamine D2 receptors have been considered as not only valuable tools for 
dissecting the roles of D2-mediated G protein-dependent and independent signaling pathways, but also better antipsychotic drug candidates 
for neurological and psychiatric disorders including schizophrenia. Consequently, functionally selective D2R ligands have also been increasingly 
pursued by the biomedical community as promising antipsychotic therapeutics with improved efficacy and reduced side effects compared with 
unbiased ligands. This review will discuss the recent development in the discovery of functional selective D2R ligands Figure 1.
Figure 1: Functional selective D2R ligands.
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With all currently FDA-approved antipsychotic drugs 
target primarily the dopamine D2 receptor (D2R) for their 
reaction [15-18], it is indicated that opposing dopamine 
signaling is central for alleviating psychotic symptoms with 
schizophrenia [19]. Clinical observations have revealed that 
schizophrenia-like symptoms occur in amphetamine abusers 
due to excessive dopamine release [20]. Also baseline dopamine 
levels and stimulated release of dopamine are found to be 
abnormal in mesolimbic systems of brains from schizophrenic 
patients [21]. All these evidences have put dopamine receptor, 
especially dopamine D2R at the center for the development of 
antipsychotic drug. Antagonists and partial agonists of D2R have 
been extensively pursued as antipsychotic therapeutics for the 
treatment of schizophrenia [22,23]. 
As a member in the big family of G protein-coupled receptors 
(GPCR), dopamine D2 receptor (D2R) is Gαi/o coupled whose 
activation inhibits CAMP production [24]. Antipsychotic drugs 
targeting D2R were originally identified as being able to bind to 
D2R and regulate CAMP synthesis [18]. Mounting evident from 
recent studies indicate that D2R signal not only via canonical 
pathway involving hetero trimeric large G protein, but also 
via noncanonical G protein-independent pathways with other 
signaling proteins including, most prominently, β-arrestins [25-
28]. Most antipsychotic drugs have been found to have both G 
protein-dependant and G protein-independent actions [28]. 
The process by which GPCR ligands, including D2R ligands, 
differentially modulate canonical and noncanonical signal 
transduction pathways is a phenomenon known as “functional 
selectivity” or “biased agonism” [29,30]. 
With functionally selective D2R ligands that can preferentially 
activate either canonical or noncanonical D2 signaling pathways 
[31,32], it is thus very clear that the D2R ligands with discrete 
functional selectivity profiles will be extremely useful for 
elucidating the key signal transduction pathways essential for 
both the therapeutic actions and the side effects of antipsychotic 
drugs [30]. And this understanding will in turn enable the design 
of better antipsychotic drug candidates, which can ultimately 
lead to safer and more effective therapies for schizophrenia 
patients. In this short review article, we will summarize the 
recent development in the discovery of functional selective D2R 
ligands for the treatment of schizophrenia.
Functional Selective D2RLigands
Aripiprizole
Aripiprazole (OPC-14597, 1), an FDA-approved atypical 
antipsychotic drug, was one of the first functionally selective D2R 
ligands identified [31,33,34]. It has an excellent side-effect profile 
presumed, in part, to be due to lack of typical D2R antagonist 
properties. Although aripiprazole was initially described as a 
partial D2R agonist, on the basis of assays performed in whole 
animals and isolated tissues [35-37], it was later demonstrated 
that aripiprazole could behave as a full agonist, a partial agonist, 
or an antagonist at D2R depending upon the signaling readout 
and cell type interrogated [28,31,33,38]. 
The study examined D2R binding properties of aripiprazole 
as well as the effects of the drug on three downstream D2R-
mediated functional effectors including mitogen-activated 
protein kinase (MAPK) phosphorylation, potentiation of 
arachidonic acid (AA) release, and D2R internalization revealed 
that aripiprazole affects D2L-mediated signaling pathways in a 
differential manner [31]. In the study examining the properties 
of aripiprazole at D2 like auto receptors by monitoring the 
changes of dopamine synthesis in adult rat brain striatal minces 
incubated ex vivo, it was found that alteration of dopaminergic 
tone by depolarization affected the actions of aripiprazole on D₂-
like auto receptors [39]. 
The in vivo study aimed to investigate the effects of 
aripiprazole on the D2R downstream cAMP-PKA and Akt-GSK3β 
signaling pathways suggested that aripiprazole had differential 
effects on the cAMP-PKA and Akt-GSK3β signaling pathways in 
the brain areas [40]. Additional studies examined the activity 
of aripiprazole in D2R-mediated heterologous sensitization of 
adenylyl cyclase and cell-based dynamic mass redistribution 
(DMR). Aripiprazole displayed a unique functional profile for 
modulation of G proteins, being a partial agonist for Gαi/o and 
a robust antagonist for Gβγ signaling. Additionally, aripiprazole 
was a weak partial agonist for both heterologous sensitization 
and dynamic mass redistribution [41]. 
UNC9975 (2), UNC0006 (3) and UNC9994 (4)
Through a robust diversity-oriented multi-dimensional 
modification of the scaffold represented by aripiprazole (1), Three 
β-arrestin-biased D2R ligands including UNC9975 (2), UNC0006 
(3), and UNC9994 (4) were reported as the unprecedented 
β-arrestin-biased ligands for a Gi-coupled G protein–coupled 
receptor (GPCR) [42]. All three D2R ligands were simultaneously 
antagonists of Gi-regulated CAMP production and partial 
agonists for D2R/β-arrestin-2 interactions. Importantly, 
UNC9975 displayed potent antipsychotic-like activity without 
inducing motoric side effects in inbred C57BL/6 mice in vivo. 
Genetic deletion of β-arrestin-2 simultaneously attenuated 
the antipsychotic actions of UNC9975 and transformed it into 
a typical antipsychotic drug with a high propensity to induce 
catalepsy. 
Similarly, the antipsychotic-like activity displayed by 
UNC9994, an extremely β-arrestin-biased D2R agonist, in wild-
type mice was completely abolished in β-arrestin-2 knockout 
mice. These results suggest that β-arrestin signaling and 
recruitment can be simultaneously a significant contributor 
to antipsychotic efficacy and protective against motoric side 
effects [42]. Follow-up comprehensive structure-functional 
selectivity relationship studies (SFSR) focused on four regions 
of aripiprazole scaffold (e.g. left hand side phenyl region, 
middle amino region, central linker region, and right hand side 
How to cite this article:  Xin C, Giuseppe G. Functional Selective D2 Ligands for the Treatment of Schizophrenia. Nov Appro Drug Des Dev. 2017; 3(1) 
: 555602003
Novel Approaches in Drug Designing & Development
bicyclic aromatic region) resulted in more β-arrestin biased D2R 
agonists [43]. 
This combined medicinal chemistry and pharmacological 
profiling approach also provided the biomedical community a 
successful proof-of-concept for how functionally selective ligands 
can be discovered. The study designed to test the effectiveness 
of UNC9975 or UNC9994 on schizophrenia-like behaviors in 
phencyclidine treated or NR1-knockdown hypoglutamatergic 
mice showed that the UNC compounds reduced hyper 
locomotion in the open field, restored PPI, improved novel 
object recognition memory, partially normalized social behavior, 
decreased conditioned avoidance responding, and elicit a much 
lower level of catalepsy than haloperidol [44]. These preclinical 
results suggest that exploitation of functional selectivity may 
provide unique opportunities to develop drugs with fewer side 
effects, greater therapeutic selectivity, and enhanced efficacy for 
treating schizophrenia and related conditions than medications 
that are currently available.
Cariprizine (5) and analogs (Compounds 6 And 7)
Cariprazine (5) is an atypical antipsychotic recently approve 
by FDA for the treatment of schizophrenia and bipolar mania 
[45]. It acts primarily as a partial agonist for D2R and D3R [46] 
with higher selectivity for D3R [46,47]. The structure-functional 
selectivity relationship (SFSR) studies of cariprazine scaffold 
carried out by Shonberg and colleagues at Monash University 
was focused on three main portions of the lead compound: 
the tertiary amine containing “head group”, the cyclohexylene 
“spacer” group, and the tert-butyl carbamate “tail group” [48]. 
Similar to the SFSR studies of aripiprazole analogs, to assess 
G protein-related signaling, the compounds were profiled in 
the D2 CAMP accumulation assay, whereas β-arrestin signaling 
was evaluated by measuring phosphorylation of extracellular 
signal-regulated kinase 1/2 (ERK 1/2). In this testing paradigm, 
cariprazine (5) displayed a 230-fold bias toward the cAMP 
pathway compared with dopamine. Interestingly, while all 
cariprazine derivatives disclosed in this letter showed a bias 
toward the G protein signaling pathway (6), subtle changes 
of the D2 unbiased partial agonist, a structurally related aryl 
piperazine reported by Tschammer [49], led to analogues that 
displayed a strong bias toward β-arrestin signaling such as 
compound 7. By combining the medicinal chemistry efforts with 
novel analytical pharmacology methods [50], it was discovered 
that the nature of the head group, the composition of the tail 
group, and the orientation, length, and flexibility of the spacer 
were all important factors for the control of functional selectivity 
at the D2R [48].
Functional selective D2R ligands with privileged 
structures (compound 8)
Another comprehensive structure activity relationship 
(SAR) studies carried out by Szabo and colleagues at Monash 
University also led to the discovery of novel functional selective 
D2R ligands [51]. They investigated the determinants of 
efficacy, affinity, and bias for three privileged structures for 
the D2R, exploring changes to linker length and incorporation 
of a heterocyclic unit. After profiling the newly synthesized 
compounds in two signaling assays (CAMP and pERK1/2), they 
were able to identify and quantify determinants of functional 
selectivity at the D2R. The results from combined medicinal 
chemistry and pharmacological profiling approach revealed 
that: 1) substitution on the phenylpiperazine privileged 
structures (2-methoxy vs 2,3-dichloro) influenced bias when the 
thienopyridine heterocycle was absent; and 2) upon inclusion of 
the thienopyridine unit, the substitution pattern (4,6-dimethyl 
vs 5-chloro-6-methoxy-4-methyl) had a significant effect on bias 
that overruled the effect of the phenylpiperazine substitution 
pattern [51]. This latter observation could be reconciled with 
an extended binding mode for these compounds, whereby the 
interaction of the heterocycle with a secondary binding pocket 
may bring functional selectivity to the parent compounds. The 
resulted novel D2R partial agonists, 8 and 9, display a similar 
affinity for the D2R as aripiprazole but exhibit distinct functional 
selectivity profiles, which made them useful tools to explore the 
contribution of functional selectivity to antipsychotic efficacy.
Functional selective D2R/D3R partial agonists
Dopamine D2R and D3R are known as valuable targets 
for the treatment of neurological and psychiatric disorders 
including schizophrenia [52-54]. Hiller and colleagues evaluated 
a series of newly synthesized compounds for their ability to 
differentially activate distinct signaling pathways [55]. 
Measurement of D2L- and D2S-mediated [35S] GTPγS 
incorporation in the presence of coexpressed Gαo and Gαi 
subunits showed significantly biased receptor activation for 
several test compounds [55]. A follow-up study from the same 
group using the same evaluation methods yielded the most 
striking functionally selective D2R ligand, carbaldoxime 8b (9, 
Gαo1, pEC50 = 8.87, Emax = 65%; Gαi2, pEC50 = 6.63, Emax=27%) 
[56]. It was also indicated in the study that 1,4-disubstituted 
aromatic piperazines (1,4-DAPs) behaved as antagonists for 
β-arrestin-2 recruitment, implying significant ligand bias for 
G-protein activation over β-arrestin-2 recruitment at D2R. 
Regiochemistry and the nature of functional groups attached to 
the pyrazolo [1,5-a]pyridine moiety strongly influence ligand 
efficacy and selectivity between D2R and D3R activation [56].
Other functional selective D2 ligands
Intensive structural exploration on aripiprazole scaffold 
engendered UNC2438 (10) which was found to be a G-protein 
biased compounds [57]. Further structure-functional selectivity 
relationship studies (SFSR) on UNC2438 focused on the 
right hand side benzothiazole moiety and the left hand side 
phenylpiperazine moiety furnished a few additional G-protein 
biased compounds which were partial agonists in D2R Gio-
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mediated CAMP inhibition assay and simultaneously inactive in 
D2R-mediated β-arrestin-2 recruitment assay [57]. 
Most recently, a tailored virtual library with close to 13,000 
compounds bearing 2,3-dichlorophenylpiperazine, a privileged 
orthosteric scaffold, connected to diverse chemical moieties via 
a linker was docked to the D2R model [58]. Eighteen top-ranked 
compounds that occupied both the orthosteric and allosteric site 
were synthesized, leading to the discovery of 16 partial agonists. 
While a majority of the ligands had comparable maximum 
effects in the G protein and β-arrestin recruitment assays, 
some displayed preference for a single pathway. In particular, 
compound 11 stimulated β-arrestin recruitment (EC50 = 320 
nM, Emax = 16%) but had no detectable G protein signaling. 
Conclusion
The growing realization of the complexity of G protein 
coupled receptor (GPCR) mediated signal transduction pathways, 
specifically D2R mediated signaling pathways, has provided 
a theoretical framework for the development of functionally 
selective or biased ligands. Several studies have demonstrated 
that agonists differ in their ability to activate various pathways. 
Notably, blockade of β-arrest in recruitment was found to be a 
shared property of antipsychotics that exhibit either antagonist 
(e.g., haloperidol), or partial agonist (e.g., aripiprazole) activity 
through Gai/o-CAMP pathways [28]. In contrast, a study with 
analogs of the novel antipsychotic aripiprazole suggested that 
D2 ligands with Gai/o antagonist and β-arrestin agonist activity 
may have antipsychotic behavioral activity with reduced extra 
pyramidal side effects in a mouse model [3]. While there are 
still a lot of questions to be answered in this field, heightened 
awareness of the potential benefit of pathway biased D2R ligands 
has inspired scientists in this area develop more functionally 
selective D2R ligands as better antipsychotic therapies for 
schizophrenia.
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